Tian X, Shi C, Liu S, Zhao C, Wang X, Cao Y
J Dent Sci. 2023; 18(1):57-64.
PMID: 36643267
PMC: 9831828.
DOI: 10.1016/j.jds.2022.07.010.
Ye S, Wang D, Jin M, Du J, Chen X, Zhang H
J Clin Lab Anal. 2022; 37(1):e24820.
PMID: 36550070
PMC: 9833988.
DOI: 10.1002/jcla.24820.
Shi C, Liu S, Tian X, Miao C, Wang R, Ma X
Sci Rep. 2022; 12(1):11400.
PMID: 35794182
PMC: 9259703.
DOI: 10.1038/s41598-022-15534-7.
Baumeister P, Zhou J, Canis M, Gires O
Cancers (Basel). 2021; 13(21).
PMID: 34771518
PMC: 8582421.
DOI: 10.3390/cancers13215355.
McCarthy C, Fedele S, Ottensmeier C, Shaw R
Cancers (Basel). 2021; 13(15).
PMID: 34359746
PMC: 8345124.
DOI: 10.3390/cancers13153845.
Methylation-Driven Genes Identified as Novel Prognostic Indicators for Thyroid Carcinoma.
Lv L, Cao L, Hu G, Shen Q, Wu J
Front Genet. 2020; 11:294.
PMID: 32296463
PMC: 7136565.
DOI: 10.3389/fgene.2020.00294.
DNA methylation-mediated Klotho silencing is an independent prognostic biomarker of head and neck squamous carcinoma.
Zhu Y, Cao X, Zhang X, Chen Q, Wen L, Wang P
Cancer Manag Res. 2019; 11:1383-1390.
PMID: 30863149
PMC: 6388988.
DOI: 10.2147/CMAR.S188415.
DNA methylation biomarkers for head and neck squamous cell carcinoma.
Zhou C, Ye M, Ni S, Li Q, Ye D, Li J
Epigenetics. 2018; 13(4):398-409.
PMID: 29927694
PMC: 6140809.
DOI: 10.1080/15592294.2018.1465790.
Deciphering the Role of the Barr Body in Malignancy: An insight into head and neck cancer.
Sharma D, Koshy G, Gupta S, Sharma B, Grover S
Sultan Qaboos Univ Med J. 2018; 17(4):e389-e397.
PMID: 29372079
PMC: 5766293.
DOI: 10.18295/squmj.2017.17.04.003.
Analysis of Site-Specific Methylation of Tumor-Related Genes in Head and Neck Cancer: Potential Utility as Biomarkers for Prognosis.
Misawa K, Mochizuki D, Imai A, Mima M, Misawa Y, Mineta H
Cancers (Basel). 2018; 10(1).
PMID: 29361757
PMC: 5789377.
DOI: 10.3390/cancers10010027.
Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho R, Squarize C, Almeida L
Int J Mol Sci. 2017; 18(7).
PMID: 28704968
PMC: 5535996.
DOI: 10.3390/ijms18071506.
Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers.
Lim Y, Wan Y, Vagenas D, Ovchinnikov D, Perry C, Davis M
BMC Cancer. 2016; 16(1):749.
PMID: 27663357
PMC: 5034533.
DOI: 10.1186/s12885-016-2785-0.
Aberrant Methylation of MGMT Promoter in HNSCC: A Meta-Analysis.
Cai F, Xiao X, Niu X, Shi H, Zhong Y
PLoS One. 2016; 11(9):e0163534.
PMID: 27657735
PMC: 5033341.
DOI: 10.1371/journal.pone.0163534.
WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report.
Ribeiro I, Caramelo F, Marques F, Domingues A, Mesquita M, Barroso L
Cell Oncol (Dordr). 2016; 39(6):573-582.
PMID: 27491556
DOI: 10.1007/s13402-016-0293-5.
NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
Virani S, Bellile E, Bradford C, Carey T, Chepeha D, Colacino J
BMC Cancer. 2015; 15:825.
PMID: 26518708
PMC: 4628358.
DOI: 10.1186/s12885-015-1806-8.
Genome-Wide Scan for Methylation Profiles in Keloids.
Jones L, Young W, Divine G, Datta I, Chen K, Ozog D
Dis Markers. 2015; 2015:943176.
PMID: 26074660
PMC: 4446486.
DOI: 10.1155/2015/943176.
Epigenetic changes in the CDKN2A locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma.
Schlecht N, Ben-Dayan M, Anayannis N, Lleras R, Thomas C, Wang Y
Cancer Med. 2015; 4(3):342-53.
PMID: 25619363
PMC: 4380960.
DOI: 10.1002/cam4.374.
HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas.
Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M
J Clin Invest. 2013; 123(6):2488-501.
PMID: 23635773
PMC: 3668826.
DOI: 10.1172/JCI67010.
Molecular characterization of head and neck cancer: how close to personalized targeted therapy?.
Worsham M, Ali H, Dragovic J, Schweitzer V
Mol Diagn Ther. 2012; 16(4):209-22.
PMID: 22873739
PMC: 3707609.
DOI: 10.2165/11635330-000000000-00000.